发明申请
US20130072550A1 PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPalpha SECRETION AND IMROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
审中-公开
PKC激活作为增强sAPPalpha分泌和使用BRYOSTATIN型化合物的感染的手段
- 专利标题： PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPalpha SECRETION AND IMROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
- 专利标题（中）： PKC激活作为增强sAPPalpha分泌和使用BRYOSTATIN型化合物的感染的手段
-
申请号： US13608874申请日： 2012-09-10
-
公开(公告)号： US20130072550A1公开(公告)日： 2013-03-21
- 发明人: Rene Etcheberrigaray , Daniel L. Alkon
- 申请人： Rene Etcheberrigaray , Daniel L. Alkon
- 专利权人： Blanchette Rockefeller Neurosciences Institute
- 当前专利权人： Blanchette Rockefeller Neurosciences Institute
- 主分类号： A61K31/365
- IPC分类号： A61K31/365 ; A61P25/28 ; A61P25/00
摘要：
The present disclosure relates to methods of administering compounds for treating conditions associated with amyloid processing such as Alzheimer's Disease. Methods are disclosed comprising the step of administering a macrocyclic lactone, a benzolactam, a pyrrolidinone or a combination thereof to a subject in need in an amount effective to decrease soluble Aβ-40 or Aβ-42, or to lower total amyloid precursor protein (“APP”). Methods are also disclosed further comprising the step of identifying a subject with increased soluble Aβ-40 or Aβ-42 levels, or elevated APP levels compared to a control population.